Effects of curcumin on HDL functionality

Pharmacological Research

Volumn 119, Issue , 2017, Pages 208-218

  Ganjali, Shiva ^a   Blesso, Christopher N ^b   Banach, Maciej ^c,d   Pirro, Matteo ^e   Majeed, Muhammed ^f   Sahebkar, Amirhossein ^g,h  

^a MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b UNIVERSITY OF CONNECTICUT   (United States)

^c MEDICAL UNIVERSITY OF LODZ   (Poland)

^d POLISH MOTHER S MEMORIAL HOSPITAL RESEARCH INSTITUTE   (Poland)

^e UNIVERSITY OF PERUGIA   (Italy)

^f SABINSA CORPORATION   (United States)

^g MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^h UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

Atherosclerosis; Cholesterol efflux; Curcumin; Dyslipidemia; High density lipoprotein

Indexed keywords

APOLIPOPROTEIN A1; ARYLDIALKYLPHOSPHATASE 1; CHOLESTEROL ESTER TRANSFER PROTEIN; CURCUMA LONGA EXTRACT; CURCUMIN; DEMETHOXYCURCUMIN; DIHYDROCURUCMIN; DIPHENYL DIFLUOROKETONE; HEXAHYDROCURCUMIN; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; MICRORNA; MYELOPEROXIDASE; PHOSPHATIDYLCHOLINE STEROL ACYLTRANSFERASE; PHOSPHOLIPASE A2; PIPERINE; PLACEBO; ROSMARINIC ACID; SERUM AMYLOID A; SPHINGOSINE 1 PHOSPHATE; TETRAHYDROCURCUMIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; ANTIOXIDANT; NONSTEROID ANTIINFLAMMATORY AGENT;

ANTIINFLAMMATORY ACTIVITY; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CHOLESTEROL TRANSPORT; DRUG MECHANISM; DRUG PROTEIN BINDING; GENE EXPRESSION REGULATION; HEART INFARCTION; HUMAN; HYPERLIPIDEMIA; INFLAMMATION; LIPOPROTEIN METABOLISM; NONALCOHOLIC FATTY LIVER; NONHUMAN; PERITONITIS; PROTEIN FUNCTION; REVIEW; SYSTEMATIC REVIEW; ANIMAL; CHEMISTRY; CURCUMA; DYSLIPIDEMIAS; METABOLISM;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIOXIDANTS; ATHEROSCLEROSIS; CURCUMA; CURCUMIN; DYSLIPIDEMIAS; HUMANS; LIPOPROTEINS, HDL;

EID: 85012237586     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2017.02.008     Document Type: Review

References (134)

1. [1] Fielding, C.J., Fielding, P.E., Molecular physiology of reverse cholesterol transport. J. Lipid Res. 36:2 (1995), 211–228.
2. [2] Dragan, S., Serban, C., Banach, M., Can we change the functionality of HDL cholesterol with nonpharmacological and pharmacological agents?. Curr. Med. Chem. 21:25 (2014), 2927–2946.
3. [3] Rysz-Górzyńska, M., Banach, M., Subfractions of high-density lipoprotein (HDL) and dysfunctional HDL in chronic kidney disease patients. Arch. Med. Sci. 12 (2016), 844–849.
4. [4] Mulya, A., Lee, J.-Y., Gebre, A.K., Thomas, M.J., Colvin, P.L., Parks, J.S., Minimal lipidation of pre-β HDL by ABCA1 results in reduced ability to interact with ABCA1. Arterioscler. Thromb. Vasc. Biol. 27:8 (2007), 1828–1836.
5. [5] Czarnecka, H., Yokoyama, S., Regulation of cellular cholesterol efflux by lecithin:cholesterol acyltransferase reaction through nonspecific lipid exchange. J. Biol. Chem. 271:4 (1996), 2023–2028.
6. [6] Collet, X., Tall, A.R., Serajuddin, H., Guendouzi, K., Royer, L., Oliveira, H., Barbaras, R., Jiang, X.C., Francone, O.L., Remodeling of HDL by CETP in vivo and by CETP and hepatic lipase in vitro results in enhanced uptake of HDL CE by cells expressing scavenger receptor B-I. J. Lipid Res. 40:7 (1999), 1185–1193.
7. [7] Adorni, M.P., Zimetti, F., Billheimer, J.T., Wang, N., Rader, D.J., Phillips, M.C., Rothblat, G.H., The roles of different pathways in the release of cholesterol from macrophages. J. Lipid Res. 48:11 (2007), 2453–2462.
8. [8] Acton, S., Rigotti, A., Landschulz, K.T., Xu, S., Hobbs, H.H., Krieger, M., Identification of scavenger receptor SR-BI as a high density lipoprotein receptor. Science (New York, N. Y.) 271:5248 (1996), 518–520.
9. [9] Röhrl, C., Stangl, H., HDL. endocytosis and resecretion. Biochim. Biophys. Acta (BBA)—Mol. Cell Biol. Lipids 1831:11 (2013), 1626–1633.
10. [10] Pirro, M., Vaudo, G., Lupattelli, G., Pasqualini, L., Mannarino, M.R., Schillaci, G., Alaeddin, A., Paciullo, F., Fallarino, F., Bagaglia, F., Mannarino, E., On-treatment C-reactive protein and HDL cholesterol levels in patients at intermediate cardiovascular risk: impact on carotid intima-media thickness. Life Sci. 93:8 (2013), 338–343.
11. [11] Gordon, D.J., Probstfield, J.L., Garrison, R.J., Neaton, J.D., Castelli, W.P., Knoke, J.D., Jacobs, D.R., Bangdiwala, S., Tyroler, H.A., High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation 79:1 (1989), 8–15.
12. [12] Barter, P.J., Caulfield, M., Eriksson, M., Grundy, S.M., Kastelein, J.J., Komajda, M., Lopez-Sendon, J., Mosca, L., Tardif, J.C., Waters, D.D., Shear, C.L., Revkin, J.H., Buhr, K.A., Fisher, M.R., Tall, A.R., Brewer, B., Effects of torcetrapib in patients at high risk for coronary events. N. Engl. J. Med. 357:21 (2007), 2109–2122.
13. [13] Voight, B.F., Peloso, G.M., Orho-Melander, M., Frikke-Schmidt, R., Barbalic, M., Jensen, M.K., Hindy, G., Holm, H., Ding, E.L., Johnson, T., Schunkert, H., Samani, N.J., Clarke, R., Hopewell, J.C., Thompson, J.F., Li, M., Thorleifsson, G., Newton-Cheh, C., Musunuru, K., Pirruccello, J.P., Saleheen, D., Chen, L., Stewart, A., Schillert, A., Thorsteinsdottir, U., Thorgeirsson, G., Anand, S., Engert, J.C., Morgan, T., Spertus, J., Stoll, M., Berger, K., Martinelli, N., Girelli, D., McKeown, P.P., Patterson, C.C., Epstein, S.E., Devaney, J., Burnett, M.S., Mooser, V., Ripatti, S., Surakka, I., Nieminen, M.S., Sinisalo, J., Lokki, M.L., Perola, M., Havulinna, A., de Faire, U., Gigante, B., Ingelsson, E., Zeller, T., Wild, P., de Bakker, P.I., Klungel, O.H., Maitland-van der Zee, A.H., Peters, B.J., de Boer, A., Grobbee, D.E., Kamphuisen, P.W., Deneer, V.H., Elbers, C.C., Onland-Moret, N.C., Hofker, M.H., Wijmenga, C., Verschuren, W.M., Boer, J.M., van der Schouw, Y.T., Rasheed, A., Frossard, P., Demissie, S., Willer, C., Do, R., Ordovas, J.M., Abecasis, G.R., Boehnke, M., Mohlke, K.L., Daly, M.J., Guiducci, C., Burtt, N.P., Surti, A., Gonzalez, E., Purcell, S., Gabriel, S., Marrugat, J., Peden, J., Erdmann, J., Diemert, P., Willenborg, C., Konig, I.R., Fischer, M., Hengstenberg, C., Ziegler, A., Buysschaert, I., Lambrechts, D., Van de Werf, F., Fox, K.A., El Mokhtari, N.E., Rubin, D., Schrezenmeir, J., Schreiber, S., Schafer, A., Danesh, J., Blankenberg, S., Roberts, R., McPherson, R., Watkins, H., Hall, A.S., Overvad, K., Rimm, E., Boerwinkle, E., Tybjaerg-Hansen, A., Cupples, L.A., Reilly, M.P., Melander, O., Mannucci, P.M., Ardissino, D., Siscovick, D., Elosua, R., Stefansson, K., O'Donnell, C.J., Salomaa, V., Rader, D.J., Peltonen, L., Schwartz, S.M., Altshuler, D., Kathiresan, S., Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. Lancet (London England) 380:9841 (2012), 572–580.
14. [14] Boden, W.E., Probstfield, J.L., Anderson, T., Chaitman, B.R., Desvignes-Nickens, P., Koprowicz, K., McBride, R., Teo, K., Weintraub, W., Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N. Engl. J. Med. 365:24 (2011), 2255–2267.
15. [15] Otocka-Kmiecik, A., Mikhailidis, D.P., Nicholls, S.J., Davidson, M., Rysz, J., Banach, M., Dysfunctional HDL: a novel important diagnostic and therapeutic target in cardiovascular disease?. Prog. Lipid Res. 51:4 (2012), 314–324.
16. [16] Barylski, M., Toth, P.P., Nikolic, D., Banach, M., Rizzo, M., Montalto, G., Emerging therapies for raising high-density lipoprotein cholesterol (HDL-C) and augmenting HDL particle functionality. Best Pract. Res. Clin. Endocrinol. Metab. 28:3 (2014), 453–461.
17. [17] T.H.-T.C. Group, Effects of Extended-Release Niacin with Laropiprant in High-Risk Patients. New Engl. J. Med. 371:3 (2014), 203–212.
18. [18] de la Llera-Moya, M., Drazul-Schrader, D., Asztalos, B.F., Cuchel, M., Rader, D.J., Rothblat, G.H., The ability to promote efflux via ABCA1 determines the capacity of serum specimens with similar high-density lipoprotein cholesterol to remove cholesterol from macrophages. Arterioscler. Thromb. Vasc. Biol. 30:4 (2010), 796–801.
19. [19] Van Eck, M., Twisk, J., Hoekstra, M., Van Rij, B.T., Van der Lans, C.A., Bos, I.S.T., Kruijt, J.K., Kuipers, F., Van Berkel, T.J., Differential effects of scavenger receptor BI deficiency on lipid metabolism in cells of the arterial wall and in the liver. J. Biol. Chem. 278:26 (2003), 23699–23705.
20. [20] Van Eck, M., Hoekstra, M., Hildebrand, R.B., Yaong, Y., Stengel, D., Kruijt, J.K., Sattler, W., Tietge, U.J., Ninio, E., Van Berkel, T.J., Pratico, D., Increased oxidative stress in scavenger receptor BI knockout mice with dysfunctional HDL. Arterioscler. Thromb. Vasc. Biol. 27:11 (2007), 2413–2419.
21. [21] Khera, A.V., Cuchel, M., de la Llera-Moya, M., Rodrigues, A., Burke, M.F., Jafri, K., French, B.C., Phillips, J.A., Mucksavage, M.L., Wilensky, R.L., Mohler, E.R., Rothblat, G.H., Rader, D.J., Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N. Engl. J. Med. 364:2 (2011), 127–135.
22. [22] Rohatgi, A., Khera, A., Berry, J.D., Givens, E.G., Ayers, C.R., Wedin, K.E., Neeland, I.J., Yuhanna, I.S., Rader, D.R., de Lemos, J.A., Shaul, P.W., HDL cholesterol efflux capacity and incident cardiovascular events. N. Engl. J. Med. 371:25 (2014), 2383–2393.
23. [23] Hafiane, A., Genest, J., High density lipoproteins: measurement techniques and potential biomarkers of cardiovascular risk. BBA Clin. 3 (2015), 175–188.
24. [24] Vaisar, T., Pennathur, S., Green, P.S., Gharib, S.A., Hoofnagle, A.N., Cheung, M.C., Byun, J., Vuletic, S., Kassim, S., Singh, P., Chea, H., Knopp, R.H., Brunzell, J., Geary, R., Chait, A., Zhao, X.Q., Elkon, K., Marcovina, S., Ridker, P., Oram, J.F., Heinecke, J.W., Shotgun proteomics implicates protease inhibition and complement activation in the antiinflammatory properties of HDL. J. Clin. Invest. 117:3 (2007), 746–756.
25. [25] Soran, H., Hama, S., Yadav, R., Durrington, P.N., HDL functionality. Curr. Opin. Lipidol. 23:4 (2012), 353–366.
26. [26] Pirro, M., Siepi, D., Lupattelli, G., Roscini, A.R., Schillaci, G., Gemelli, F., Vaudo, G., Marchesi, S., Pasqualini, L., Mannarino, E., Plasma C-reactive protein in subjects with hypo/hyperalphalipoproteinemias. Metabolism 52:4 (2003), 432–436.
27. [27] Navab, M., Reddy, S.T., Van Lenten, B.J., Anantharamaiah, G., Fogelman, A.M., The role of dysfunctional HDL in atherosclerosis. J. Lipid Res. 50:Suppl (2009), S145–S149.
28. [28] Van Lenten, B.J., Wagner, A.C., Navab, M., Anantharamaiah, G.M., Hama, S., Reddy, S.T., Fogelman, A.M., Lipoprotein inflammatory properties and serum amyloid A levels but not cholesterol levels predict lesion area in cholesterol-fed rabbits. J. Lipid Res. 48:11 (2007), 2344–2353.
29. [29] Han, C.Y., Chiba, T., Campbell, J.S., Fausto, N., Chaisson, M., Orasanu, G., Plutzky, J., Chait, A., Reciprocal and coordinate regulation of serum amyloid A versus apolipoprotein AI and paraoxonase-1 by inflammation in murine hepatocytes. Arterioscler. Thromb. Vasc. Biol. 26:8 (2006), 1806–1813.
30. [30] McGillicuddy, F.C., de la Llera Moya, M., Hinkle, C.C., Joshi, M.R., Chiquoine, E.H., Billheimer, J.T., Rothblat, G.H., Reilly, M.P., Inflammation impairs reverse cholesterol transport in vivo. Circulation 119:8 (2009), 1135–1145.
31. [31] Vaisar, T., Tang, C., Babenko, I., Hutchins, P., Wimberger, J., Suffredini, A.F., Heinecke, J.W., Inflammatory remodeling of the HDL proteome impairs cholesterol efflux capacity. J. Lipid Res. 56:8 (2015), 1519–1530.
32. [32] Ferretti, G., Bacchetti, T., Masciangelo, S., Bicchiega, V., HDL-paraoxonase and membrane lipid peroxidation: a comparison between healthy and obese subjects. Obesity (Silver Spring, Md) 18:6 (2010), 1079–1084.
33. [33] Navab, M., Hama, S.Y., Hough, G.P., Subbanagounder, G., Reddy, S.T., Fogelman, A.M., A cell-free assay for detecting HDL that is dysfunctional in preventing the formation of or inactivating oxidized phospholipids. J. Lipid Res. 42:8 (2001), 1308–1317.
34. [34] Senti, M., Tomas, M., Fito, M., Weinbrenner, T., Covas, M.I., Sala, J., Masia, R., Marrugat, J., Antioxidant paraoxonase 1 activity in the metabolic syndrome. J. Clin. Endocrinol. Metab. 88:11 (2003), 5422–5426.
35. [35] Mackness, M., Mackness, B., Human paraoxonase-1 (PON1): Gene structure and expression, promiscuous activities and multiple physiological roles. Gene 567:1 (2015), 12–21.
36. [36] Sahebkar, A., Hernández-Aguilera, A., Abelló, D., Sancho, E., Camps, J., Joven, J., Systematic review and meta-analysis deciphering the impact of fibrates on paraoxonase-1 status. Metabolism 65:5 (2016), 609–622.
37. [37] Ferretti, G., Bacchetti, T., Sahebkar, A., Effect of statin therapy on paraoxonase-1 status: a systematic review and meta-analysis of 25 clinical trials. Prog. Lipid Res. 60 (2015), 50–73.
38. [38] Pasqualini, L., Cortese, C., Marchesi, S., Siepi, D., Pirro, M., Vaudo, G., Liberatoscioli, L., Gnasso, A., Schillaci, G., Mannarino, E., Paraoxonase-1 activity modulates endothelial function in patients with peripheral arterial disease. Atherosclerosis 183:2 (2005), 349–354.
39. [39] van Wijk, J., Coll, B., Cabezas, M.C., Koning, E., Camps, J., Mackness, B., Joven, J., Rosiglitazone modulates fasting and post-prandial paraoxonase 1 activity in type 2 diabetic patients. Clin. Exp. Pharmacol. Physiol. 33:12 (2006), 1134–1137.
40. [40] Momtazi, A.A., Derosa, G., Maffioli, P., Banach, M., Sahebkar, A., Role of microRNAs in the therapeutic effects of curcumin in non-cancer diseases. Mol. Diagn. Ther. 20:4 (2016), 335–345.
41. [41] Ganjali, S., Sahebkar, A., Mahdipour, E., Jamialahmadi, K., Torabi, S., Akhlaghi, S., Ferns, G., Parizadeh, S.M.R., Ghayour-Mobarhan, M., Investigation of the effects of curcumin on serum cytokines in obese individuals: a randomized controlled trial. Sci. World J., 2014, 2014.
42. [42] Chen, F.Y., Zhou, J., Guo, N., Ma, W.G., Huang, X., Wang, H., Yuan, Z.Y., Curcumin retunes cholesterol transport homeostasis and inflammation response in M1 macrophage to prevent atherosclerosis. Biochem. Biophys. Res. Commun. 467:4 (2015), 872–878.
43. [43] Sahebkar, A., Curcuminoids for the management of hypertriglyceridaemia. Nat. Rev. Cardiol., 11(2), 2014.
44. [44] Shin, S.K., Ha, T.Y., McGregor, R.A., Choi, M.S., Long-term curcumin administration protects against atherosclerosis via hepatic regulation of lipoprotein cholesterol metabolism. Mol. Nutr. Food Res. 55:12 (2011), 1829–1840.
45. [45] Jang, E.M., Choi, M.S., Jung, U.J., Kim, M.J., Kim, H.J., Jeon, S.M., Shin, S.K., Seong, C.N., Lee, M.K., Beneficial effects of curcumin on hyperlipidemia and insulin resistance in high-fat-fed hamsters. Metabolism 57:11 (2008), 1576–1583.
46. [46] Tu, Y.S., Sun, D.M., Zeng, X.H., Yao, N., Huang, X.J., Huang, D., Chen, Y.X., Piperine potentiates the hypocholesterolemic effect of curcumin in rats fed on a high fat diet. Exp. Ther. Med. 8:1 (2014), 260–266.
47. [47] Wang, S., Moustaid-Moussa, N., Chen, L., Mo, H., Shastri, A., Su, R., Bapat, P., Kwun, I., Shen, C.L., Novel insights of dietary polyphenols and obesity. J. Nutr. Biochem. 25:1 (2014), 1–18.
48. [48] Panahi, Y., Kianpour, P., Mohtashami, R., Jafari, R., Simental-Mendia, L.E., Sahebkar, A., Efficacy and safety of phytosomal curcumin in non-alcoholic fatty liver disease: a randomized controlled trial. Drug Res., 2017, 10.1055/s-0043-100019 (in press).
49. [49] Rezaee, R., Momtazi, A.A., Monemi, A., Sahebkar, A., Curcumin A potentially powerful tool to reverse cisplatin-induced toxicity. Pharmacol. Res. 117 (2016), 218–227.
50. [50] Mirzaei, H., Shakeri, A., Rashidi, B., Jalili, A., Banikazemi, Z., Sahebkar, A., Phytosomal curcumin: a review of pharmacokinetic experimental and clinical studies. Biomed. Pharmacother. 85 (2017), 102–112.
51. [51] Teymouri, M., Pirro, M., Johnston, T.P., Sahebkar, A., Curcumin as a multifaceted compound against human papilloma virus infection and cervical cancers: a review of chemistry, cellular, molecular, and preclinical features. Biofactors, 2016, 10.1002/biof.1344 (in press).
52. [52] Lelli, D., Sahebkar, A., Johnston, T.P., Pedone, C., Curcumin use in pulmonary diseases: state of the art and future perspectives. Pharmacol. Res. 115 (2017), 133–148.
53. [53] Sahebkar, A., Henrotin, Y., Analgesic efficacy and safety of curcuminoids in clinical practice: a systematic review and meta-analysis of randomized controlled trials. Pain Med. 17:6 (2016), 1192–1202.
54. [54] Esmaily, H., Sahebkar, A., Iranshahi, M., Ganjali, S., Mohammadi, A., Ferns, G., Ghayour-Mobarhan, M., An investigation of the effects of curcumin on anxiety and depression in obese individuals: a randomized controlled trial. Chin. J. Integr. Med. 21:5 (2015), 332–338.
55. [55] Panahi, Y., Ghanei, M., Bashiri, S., Hajihashemi, A., Sahebkar, A., Short-term curcuminoid supplementation for chronic pulmonary complications due to sulfur mustard intoxication: positive results of a randomized double-blind placebo-controlled trial. Drug Res. 65:11 (2015), 567–573.
56. [56] Panahi, Y., Ghanei, M., Hajhashemi, A., Sahebkar, A., Effects of curcuminoids-piperine combination on systemic oxidative stress, clinical symptoms and quality of life in subjects with chronic pulmonary complications due to sulfur mustard: a randomized controlled trial. J. Diet. Suppl. 13:1 (2016), 93–105.
57. [57] Panahi, Y., Badeli, R., Karami, G.R., Sahebkar, A., Investigation of the efficacy of adjunctive therapy with bioavailability-boosted curcuminoids in major depressive disorder. Phytother. Res. 29:1 (2015), 17–21.
58. [58] Sahebkar, A., Molecular mechanisms for curcumin benefits against ischemic injury. Fertil. Steril. 94:5 (2010), e75–e76 (author reply e77).
59. [59] Iranshahi, M., Sahebkar, A., Hosseini, S.T., Takasaki, M., Konoshima, T., Tokuda, H., Cancer chemopreventive activity of diversin from Ferula diversivittata in vitro and in vivo. Phytomedicine 17:3–4 (2010), 269–273.
60. [60] Dong, S.Z., Zhao, S.P., Wu, Z.H., Yang, J., Xie, X.Z., Yu, B.L., Nie, S., Curcumin promotes cholesterol efflux from adipocytes related to PPARgamma-LXRalpha-ABCA1 passway. Mol. Cell. Biochem. 358:1–2 (2011), 281–285.
61. [61] Wongcharoen, W., Phrommintikul, A., The protective role of curcumin in cardiovascular diseases. Int. J. Cardiol. 133:2 (2009), 145–151.
62. [62] Momtazi, A.A., Shahabipour, F., Khatibi, S., Johnston, T.P., Pirro, M., Sahebkar, A., Curcumin as a microRNA regulator in cancer: a review. Rev. Physiol. Biochem. Pharmacol. 171 (2016), 1–38.
63. [63] Momtazi, A.A., Derosa, G., Maffioli, P., Banach, M., Sahebkar, A., Role of microRNAs in the therapeutic effects of curcumin in non-cancer diseases. Mol. Diagn. Ther. 20:4 (2016), 335–345.
64. [64] Anand, P., Kunnumakkara, A.B., Newman, R.A., Aggarwal, B.B., Bioavailability of curcumin: problems and promises. Mol. Pharm. 4:6 (2007), 807–818.
65. [65] Gu, H.F., Li, H.Z., Tang, Y.L., Tang, X.Q., Zheng, X.L., Liao, D.F., Nicotinate-curcumin impedes foam cell formation from THP-1 cells through restoring autophagy flux. PLoS One, 11(4), 2016.
66. [66] Panahi, Y., Khalili, N., Sahebi, E., Namazi, S., Karimian, M.S., Majeed, M., Sahebkar, A., Antioxidant effects of curcuminoids in patients with type 2 diabetes mellitus: a randomized controlled trial. Inflammopharmacology 25:2 (2017), 25–31.
67. [67] Panahi, Y., Alishiri, G.H., Parvin, S., Sahebkar, A., Mitigation of systemic oxidative stress by curcuminoids in osteoarthritis: results of a randomized controlled trial. J. Diet. Suppl. 13:2 (2016), 209–220.
68. [68] Sahebkar, A., Dual effect of curcumin in preventing atherosclerosis: the potential role of pro-oxidant-antioxidant mechanisms. Nat. Prod. Res. 29:6 (2015), 491–492.
69. [69] Sahebkar, A., Mohammadi, A., Atabati, A., Rahiman, S., Tavallaie, S., Iranshahi, M., Akhlaghi, S., Ferns, G.A., Ghayour-Mobarhan, M., Curcuminoids modulate pro-oxidant-antioxidant balance but not the immune response to heat shock protein 27 and oxidized LDL in obese individuals. Phytother. Res. 27:12 (2013), 1883–1888.
70. [70] Panahi, Y., Sahebkar, A., Amiri, M., Davoudi, S.M., Beiraghdar, F., Hoseininejad, S.L., Kolivand, M., Improvement of sulphur mustard-induced chronic pruritus, quality of life and antioxidant status by curcumin: results of a randomised, double-blind, placebo-controlled trial. Br. J. Nutr. 108:7 (2012), 1272–1279.
71. [71] Abdollahi, E., Momtazi, A.A., Johnston, T.P., Sahebkar, A., Therapeutic effects of curcumin in inflammatory and immune-mediated diseases: a nature-made jack-of-all-trades?. J. Cell. Physiol., 2017, 10.1002/jcp.25778 (in press).
72. [72] Karimian, M.S., Pirro, M., Majeed, M., Sahebkar, A., Curcumin as a natural regulator of monocyte chemoattractant protein-1. Cytokine Growth Factor Rev., 2016, 10.1016/j.cytogfr.2016.10.001 (in press).
73. [73] Ghandadi, M., Sahebkar, A., Curcumin: an effective inhibitor of interleukin-6. Curr. Pharm. Des., 2016.
74. [74] Panahi, Y., Hosseini, M.S., Khalili, N., Naimi, E., Simental-Mendia, L.E., Majeed, M., Sahebkar, A., Effects of curcumin on serum cytokine concentrations in subjects with metabolic syndrome: a post-hoc analysis of a randomized controlled trial. Biomed. Pharmacother. 82 (2016), 578–582.
75. [75] Derosa, G., Maffioli, P., Simental-Mendia, L.E., Bo, S., Sahebkar, A., Effect of curcumin on circulating interleukin-6 concentrations: a systematic review and meta-analysis of randomized controlled trials. Pharmacol. Res. 111 (2016), 394–404.
76. [76] Panahi, Y., Hosseini, M.S., Khalili, N., Naimi, E., Soflaei, S.S., Majeed, M., Sahebkar, A., Effects of supplementation with curcumin on serum adipokine concentrations: a randomized controlled trial. Nutrition 32:10 (2016), 1116–1122.
77. [77] Sahebkar, A., Cicero, A.F., Simental-Mendia, L.E., Aggarwal, B.B., Gupta, S.C., Curcumin downregulates human tumor necrosis factor-alpha levels: a systematic review and meta-analysis ofrandomized controlled trials. Pharmacol. Res. 107 (2016), 234–242.
78. [78] Panahi, Y., Hosseini, M.S., Khalili, N., Naimi, E., Majeed, M., Sahebkar, A., Antioxidant and anti-inflammatory effects of curcuminoid-piperine combination in subjects with metabolic syndrome: a randomized controlled trial and an updated meta-analysis. Clin. Nutr. 34:6 (2015), 1101–1108.
79. [79] Ganjali, S., Sahebkar, A., Mahdipour, E., Jamialahmadi, K., Torabi, S., Akhlaghi, S., Ferns, G., Parizadeh, S.M., Ghayour-Mobarhan, M., Investigation of the effects of curcumin on serum cytokines in obese individuals: a randomized controlled trial. Sci. World J., 2014, 2014, 898361.
80. [80] Sahebkar, A., Are curcuminoids effective C-reactive protein-lowering agents in clinical practice? Evidence from a meta-analysis. Phytother. Res. 28:5 (2014), 633–642.
81. [81] Panahi, Y., Sahebkar, A., Parvin, S., Saadat, A., A randomized controlled trial on the anti-inflammatory effects of curcumin in patients with chronic sulphur mustard-induced cutaneous complications. Ann. Clin. Biochem. 49:Pt. 6 (2012), 580–588.
82. [82] Rao, D.S., Sekhara, N.C., Satyanarayana, M.N., Srinivasan, M., Effect of curcumin on serum and liver cholesterol levels in the rat. J. Nutr. 100:11 (1970), 1307–1315.
83. [83] Elseweidy, M.M., Younis, N.N., Elswefy, S.E., Abdallah, F.R., El-Dahmy, S.I., Elnagar, G., Kassem, H.M., Atheroprotective potentials of curcuminoids against ginger extract in hypercholesterolaemic rabbits. Nat. Prod. Res. 29:10 (2015), 961–965.
84. [84] Yasni, S., Imaizumi, K., Nakamura, M., Aimoto, J., Sugano, M., Effects of Curcuma xanthorrhiza Roxb. and curcuminoids on the level of serum and liver lipids, serum apolipoprotein A-I and lipogenic enzymes in rats. Food Chem. Toxicol. 31:3 (1993), 213–218.
85. [85] Tian, M., Zhang, X., Wang, L., Li, Y., Curcumin induces ABCA1 expression and apolipoprotein A-I-mediated cholesterol transmembrane in the chronic cerebral hypoperfusion aging rats. Am. J. Chin. Med. 41:5 (2013), 1027–1042.
86. [86] Zingg, J.M., Hasan, S.T., Nakagawa, K., Canepa, E., Ricciarelli, R., Villacorta, L., Azzi, A., Meydani, M., Modulation of cAMP levels by high-fat diet and curcumin and regulatory effects on CD36/FAT scavenger receptor/fatty acids transporter gene expression. Biofactors, 2016, 10.1002/biof.1307 (in press).
87. [87] Sahebkar, A., Curcuminoids for the management of hypertriglyceridaemia. Nat. Rev. Cardiol., 11(2), 2014, 123.
88. [88] Panahi, Y., Khalili, N., Hosseini, M.S., Abbasinazari, M., Sahebkar, A., Lipid-modifying effects of adjunctive therapy with curcuminoids–piperine combination in patients with metabolic syndrome: results of a randomized controlled trial. Complement. Ther. Med. 22:5 (2014), 851–857.
89. [89] Sahebkar, A., Why it is necessary to translate curcumin into clinical practice for the prevention and treatment of metabolic syndrome?. Biofactors 39:2 (2013), 197–208.
90. [90] Mohammadi, A., Sahebkar, A., Iranshahi, M., Amini, M., Khojasteh, R., Ghayour-Mobarhan, M., Ferns, G.A., Effects of supplementation with curcuminoids on dyslipidemia in obese patients: a randomized crossover trial. Phytother. Res. 27:3 (2013), 374–379.
91. [91] Sahebkar, A., Are curcuminoids effective C-reactive protein-lowering agents in clinical practice? Evidence from a meta-analysis. Phytother. Res. 28:5 (2014), 633–642.
92. [92] Narges Amel, Z., Matteo, P., Thomas, P.J., Amirhossein, S., Is there a role for curcumin supplementation in the treatment of non-Alcoholic fatty liver disease? the data suggest yes. Curr. Pharm. Des. 22 (2016), 1–14.
93. [93] Sahebkar, A., Cicero, A.F.G., Simental-Mendía, L.E., Aggarwal, B.B., Gupta, S.C., Curcumin downregulates human tumor necrosis factor-α levels: a systematic review and meta-analysis ofrandomized controlled trials. Pharmacol. Res. 107 (2016), 234–242.
94. [94] Sahebkar, A., Henrotin, Y., Analgesic efficacy and safety of curcuminoids in clinical practice: a systematic review and meta-analysis of randomized controlled trials. Pain Med. 17:6 (2015), 1192–1202.
95. [95] Rahmani, S., Asgary, S., Askari, G., Keshvari, M., Hatamipour, M., Feizi, A., Sahebkar, A., Treatment of non-alcoholic fatty liver disease with curcumin: a randomized placebo-controlled trial. Phytother. Res. 30:9 (2016), 1540–1548.
96. [96] Panahi, Y., Kianpour, P., Mohtashami, R., Jafari, R., Simental-Mendía, L.E., Sahebkar, A., Curcumin lowers serum lipids and uric acid in subjects with nonalcoholic fatty liver disease: a randomized controlled trial. J. Cardiovasc. Pharmacol. 68:3 (2016), 223–229.
97. [97] Ramırez-Boscá, A., Soler, A., Carrion, M.A., Dıaz-Alperi, J., Bernd, A., Quintanilla, C., Almagro, E.Q., Miquel, J., An hydroalcoholic extract of Curcuma longa lowers the apo B/apo A ratio: implications for atherogenesis prevention. Mech. Ageing Dev. 119:1 (2000), 41–47.
98. [98] Zhao, J.F., Ching, L.C., Huang, Y.C., Chen, C.Y., Chiang, A.N., Kou, Y.R., Shyue, S.K., Lee, T.S., Molecular mechanism of curcumin on the suppression of cholesterol accumulation in macrophage foam cells and atherosclerosis. Mol. Nutr. Food Res. 56:5 (2012), 691–701.
99. [99] Yu, X.H., Fu, Y.C., Zhang, D.W., Yin, K., Tang, C.K., Foam cells in atherosclerosis. Clin. Chim. Acta 424 (2013), 245–252.
100. [100] Lin, X.L., Liu, M.H., Hu, H.J., Feng, H.R., Fan, X.J., Zou, W.W., Pan, Y.Q., Hu, X.M., Wang, Z., Curcumin enhanced cholesterol efflux by upregulating ABCA1 expression through AMPK-SIRT1-LXRα signaling in THP-1 macrophage-derived foam cells. DNA Cell Biol. 34:9 (2015), 561–572.
101. [101] Liu, T., Li, C., Sun, H., Luo, T., Tan, Y., Tian, D., Guo, Z., Curcumin inhibits monocyte chemoattractant protein-1 expression and enhances cholesterol efflux by suppressing the c-Jun N-terminal kinase pathway in macrophage. Inflamm. Res. 63:10 (2014), 841–850.
102. [102] Peschel, D., Koerting, R., Nass, N., Curcumin induces changes in expression of genes involved in cholesterol homeostasis. J. Nutr. Biochem. 18:2 (2007), 113–119.
103. [103] Masson, D., Jiang, X.-C., Lagrost, L., Tall, A.R., The role of plasma lipid transfer proteins in lipoprotein metabolism and atherogenesis. J. Lipid Res. 50:Suppl (2009), S201–S206.
104. [104] Prabu, R.M., Sumedha, N., Ameliorative potential of dimethoxy-curcumin effect on lipid profile and changes in tissue fatty acid composi-tion in arsenic intoxicated rats. Advances in Dyslipidemia, 2016, Avid Science, Telangana, India, 2–23 (Chapter 2).
105. [105] Nirmal, N., Om Praba, G., Velmurugan, D., Modeling studies on phospholipase A2-inhibitor complexes. Indian J. Biochem. Biophys. 45:4 (2008), 256–262.
106. [106] Dileep, K.V., Tintu, I., Sadasivan, C., Molecular docking studies of curcumin analogs with phospholipase A2. Interdiscip. Sci.: Comput. Life Sci. 3:3 (2011), 189–197.
107. [107] Ahmad, W., Kumolosasi, E., Jantan, I., Jasamai, M., Salim, E., Modulatory effect of phytoestrogens and curcumin on induction of annexin 1 in human peripheral blood mononuclear cells and their inhibitory effect on secretory phospholipase A2. Trop. J. Pharm. Res. 13:2 (2014), 171–177.
108. [108] Shao, B., Pennathur, S., Heinecke, J.W., Myeloperoxidase targets apolipoprotein A-I, the major high density lipoprotein protein, for site-specific oxidation in human atherosclerotic lesions. J. Biol. Chem. 287:9 (2012), 6375–6386.
109. [109] Bergt, C., Pennathur, S., Fu, X., Byun, J., O'Brien, K., McDonald, T.O., Singh, P., Anantharamaiah, G.M., Chait, A., Brunzell, J., Geary, R.L., Oram, J.F., Heinecke, J.W., The myeloperoxidase product hypochlorous acid oxidizes HDL in the human artery wall and impairs ABCA1-dependent cholesterol transport. Proc. Natl. Acad. Sci. U. S. A. 101:35 (2004), 13032–13037.
110. [110] Cha, M.Y., Cho, H.J., Kim, C., Jung, Y.O., Kang, M.J., Murray, M.E., Hong, H.S., Choi, Y.J., Choi, H., Kim, D.K., Kim, J., Dickson, D.W., Song, H.K., Cho, J.W., Yi, E.C., Jin, S.M., Mook-Jung, I., Mitochondrial ATP synthase activity is impaired by suppressed O-GlcNAcylation in Alzheimer's disease. Hum. Mol. Genet. 24:22 (2015), 6492–6504.
111. [111] Disilvestro, R.A., Joseph, E., Zhao, S., Bomser, J., Diverse effects of a low dose supplement of lipidated curcumin in healthy middle aged people. Nutr. J., 11(1), 2012.
112. [112] Karatepe, O., Gulcicek, O.B., Adas, G., Battal, M., Kamali, G., Kemik, A., Altug, T., Karahan, S., The use of curcumin in obstructive jaundice. Arch. Med. Sci. 5:4 (2009), 513–518.
113. [113] Kim, Y.S., Park, H.J., Joo, S.Y., Hong, M.H., Kim, K.H., Hong, Y.J., Kim, J.H., Park, H.W., Jeong, M.H., Cho, J.G., Park, J.C., Ahn, Y., The protective effect of curcumin on myocardial ischemia-reperfusion injury. Korean Circul. J. 38:7 (2008), 353–359.
114. [114] Salama, A.F., Tousson, E., Shalaby, K.A.F., Hussien, H.T., Protective effect of curcumin on chloroform as by-product of water chlorination induced cardiotoxicity. Biomed. Prevent. Nutr. 4:2 (2014), 225–230.
115. [115] Shen, S.Q., Zhang, Y., Xiang, J.J., Xiong, C.L., Protective effect of curcumin against liver warm ischemia/reperfusion injury in rat model is associated with regulation of heat shock protein and antioxidant enzymes. World J. Gastroenterol. 13:13 (2007), 1953–1961.
116. [116] Zhao, J., Yu, S., Li, L., Lin, X., Zhao, Y., Curcumin reduces inflammatory reactions following transient cerebral ischemia/reperfusion injury. Neural Regener. Res. 6:3 (2011), 219–223.
117. [117] Schrader, C., Schiborr, C., Frank, J., Rimbach, G., Curcumin induces paraoxonase 1 in cultured hepatocytes in vitro but not in mouse liver in vivo. Br. J. Nutr. 105:2 (2011), 167–170.
118. [118] Lecerf, J.M., Metabolic eff ects of curcumin (obesity, circulating lipids, insulin resistance, diabetes and atherosclerosis). Phytotherapie 10 (2012), 100–104.
119. [119] Esatbeyoglu, T., Ulbrich, K., Rehberg, C., Rohn, S., Rimbach, G., Thermal stability, antioxidant, and anti-inflammatory activity of curcumin and its degradation product 4-vinyl guaiacol. Food Funct. 6:3 (2015), 887–893.
120. [120] Singh, P., Rizvi, S.I., Role of curcumin in modulating plasma PON1 arylesterase activity and susceptibility to LDL oxidation in oxidatively challenged wistar rats. Lette. Drug Des. Discov. 12:4 (2015), 319–323.
121. [121] Varatharajalu, R., Garige, M., Leckey, L.C., Reyes-Gordillo, K., Shah, R., Lakshman, M.R., Protective role of dietary curcumin in the prevention of the oxidative stress induced by chronic alcohol with respect to hepatic injury and antiatherogenic markers. Oxid. Med. Cell. Longevity, 2016, 2016.
122. [122] Yildirim, H., Sunay, F.B., Sinan, S., Kockar, F., In vivo effects of curcumin on the paraoxonase, carbonic anhydrase, glucose-6-phosphate dehydrogenase and β-glucosidase enzyme activities in dextran sulphate sodium-induced ulcerative colitis mice. J. Enzyme Inhib. Med. Chem. 31:6 (2016), 1583–1590.
123. [123] Yilmaz, Y., Taken, K., Atar, M., Ergün, M., Söylemez, H., Protective effect of curcumin on priapism and ischemia-reperfusion injury in rats. Eur. Rev. Med. Pharmacol. Sci. 19:23 (2015), 4664–4670.
124. [124] Levkau, B., HDL-S1P: cardiovascular functions, disease-associated alterations, and therapeutic applications. Front. Pharmacol., 6, 2015, 243.
125. [125] Huang, J., Huang, K., Lan, T., Xie, X., Shen, X., Liu, P., Huang, H., Curcumin ameliorates diabetic nephropathy by inhibiting the activation of the SphK1-S1P signaling pathway. Mol. Cell. Endocrinol. 365:2 (2013), 231–240.
126. [126] Lan, T., Liu, W., Xie, X., Xu, S., Huang, K., Peng, J., Shen, X., Liu, P., Wang, L., Xia, P., Huang, H., Sphingosine kinase-1 pathway mediates high glucose-induced fibronectin expression in glomerular mesangial cells. Mol. Endocrinol. 25:12 (2011), 2094–2105.
127. [127] Coetzee, G.A., Strachan, A.F., van der Westhuyzen, D.R., Hoppe, H.C., Jeenah, M.S., de Beer, F.C., Serum amyloid A-containing human high density lipoprotein 3. Density, size, and apolipoprotein composition. J. Biol. Chem. 261:21 (1986), 9644–9651.
128. [128] Leray, V., Freuchet, B., Le Bloc'h, J., Jeusette, I., Torre, C., Nguyen, P., Effect of citrus polyphenol- and curcumin-supplemented diet on inflammatory state in obese cats. Br. J. Nutr. 106:Suppl. 1 (2011), S198–201.
129. [129] Michell, D.L., Vickers, K.C., Lipoprotein carriers of microRNAs. Biochim. Biophys. Acta 1861:12 Pt. B (2016), 2069–2074.
130. [130] Rayner, K.J., Suarez, Y., Davalos, A., Parathath, S., Fitzgerald, M.L., Tamehiro, N., Fisher, E.A., Moore, K.J., Fernandez-Hernando, C., MiR-33 contributes to the regulation of cholesterol homeostasis. Science (New York, N. Y.) 328:5985 (2010), 1570–1573.
131. [131] Sun, Q., Zhang, W., Guo, Y., Li, Z., Chen, X., Wang, Y., du, Y., Zang, W., Zhao, G., Curcumin inhibits cell growth and induces cell apoptosis through upregulation of miR-33b in gastric cancer. Tumor Biol., 2016, 1–8.
132. [132] Zhang, P., Bai, H., Liu, G., Wang, H., Chen, F., Zhang, B., Zeng, P., Wu, C., Peng, C., Huang, C., Song, Y., Song, E., MicroRNA-33b, upregulated by EF24, a curcumin analog, suppresses the epithelial-to-mesenchymal transition (EMT) and migratory potential of melanoma cells by targeting HMGA2. Toxicol. Lett. 234:3 (2015), 151–161.
133. [133] Bei, W.J., Guo, J., Wu, H.Y., Cao, Y., Lipid-regulating effect of traditional chinese medicine: mechanisms of actions. Evid.-Based Complement. Altern. Med., 2012, 2012.
134. [134] Kontush, A., Chapman, M.J., Antiatherogenic small, dense HDL-guardian angel of the arterial wall? Nature clinical practice. Cardiovasc. Med. 3:3 (2006), 144–153.